Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdRad: Adjuvant Docetaxel in Intermediate/High-Risk Prostate Cancer
NCT00653848Phase 3Unknown
- Sponsor
- Scandinavian Prostate Cancer Group
- Start
- May 2007
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by Scandinavian Prostate Cancer Group. Primary endpoint: Prostate-Specific Antigen progression rate. Status: unknown.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00653848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00653848.